Back to top
more

Meridian Bioscience Inc. (VIVO)

(Delayed Data from NSDQ)

$11.51 USD

11.51
1,168,817

-0.48 (-4.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

[VIVO]

Reports for Purchase

Showing records 1 - 20 ( 81 total )

Industry: Medical - Products

Record: 1

12/13/2022

Company Report

Pages: 5

Merger Expected to Close on January 31, 2023; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 2

08/08/2022

Company Report

Pages: 5

Fiscal 3Q22 Financial Results Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 3

07/08/2022

Company Report

Pages: 5

Meridian To be Acquired for $1.53B in Cash; Downgrading to Neutral with $34 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 4

05/27/2022

Company Report

Pages: 5

qPCR Master Mixes For Monkeypox Ready to Ship; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 5

05/09/2022

Company Report

Pages: 6

Fiscal 2Q22 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 6

04/08/2022

Company Report

Pages: 5

Record Financial Performance in F2Q22 Expected; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 7

02/07/2022

Company Report

Pages: 6

Robust Performance in F1Q22; Reiterate Buy; Raising PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 8

11/15/2021

Company Report

Pages: 5

F4Q21 and Fiscal-Year 2021 Results; Reiterate Buy; Modulating PT to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 9

10/08/2021

Company Report

Pages: 5

Multiple Air-Dryable qPCR Mixes Launched; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 10

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for VIVO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 11

08/09/2021

Company Report

Pages: 6

COVID-19 Revenue Dwindles in F3Q21; Reiterate Buy; Reducing PT to $27

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 12

07/26/2021

Company Report

Pages: 6

Accretive Diagnostic Business Acquired; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 13

06/29/2021

Company Report

Pages: 6

Revogene COVID-19 Assay EUA Application Resubmitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 14

05/10/2021

Company Report

Pages: 6

Solid F2Q21 Performance; FY21 Guidance Down; Lowering PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 15

04/29/2021

Company Report

Pages: 5

New Point-of-Care Molecular Test Mix Launched; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 16

02/24/2021

Company Report

Pages: 6

Revogene SARS-CoV-2 Test EUA Delayed; Reiterate Buy; Lowering PT to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 17

02/08/2021

Company Report

Pages: 6

Record Financial Performance in F1Q21; Reiterate Buy; Raising PT to $34

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 18

02/04/2021

Company Report

Pages: 6

NIH Grant Supports SARS-CoV-2 Test Production Expansion; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 19

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 20

01/19/2021

Company Report

Pages: 6

Robust Top-Line Growth in F1Q21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party